<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM/HYPOTHESIS: <z:chebi fb="0" ids="6801">Metformin</z:chebi> is a well-known oral hypoglycaemic agent and has been commonly used, in combination with sulphonylurea, to treat type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the advantageous effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> plus sulphonylurea on <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e> has yet to be clarified </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate whether sulphonylurea or sulphonylurea plus <z:chebi fb="0" ids="6801">metformin</z:chebi> prevent <z:e sem="disease" ids="C1504375" disease_type="Disease or Syndrome" abbrv="">diabetic macroangiopathy</z:e>, we examined the progression of carotid artery intima-media thickness (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>) as a surrogate end point </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were divided into three groups, receiving the following treatments: (i) <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (n=59); (ii) <z:chebi fb="0" ids="31654">gliclazide</z:chebi> (n=30); and (iii) <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> + <z:chebi fb="0" ids="6801">metformin</z:chebi> (n=29) </plain></SENT>
<SENT sid="4" pm="."><plain>Maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> and average <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> (the greatest value among 6 average values of each 3 points including greatest thickness) were measured at the beginning and end of the observation period </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: For the follow-up period of 3 years, the annual change in average <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> of the <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> plus <z:chebi fb="0" ids="6801">metformin</z:chebi> group (0.003+/-0.048 mm) was smaller than that of the <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> group (0.064+/-0.045 mm) and <z:chebi fb="0" ids="31654">gliclazide</z:chebi> group (0.032+/-0.036 mm) (p&lt;0.0001 and p=0.043 respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>In the <z:chebi fb="0" ids="31654">gliclazide</z:chebi> group, average <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> increased during the follow-up period, but annual change in average <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> was significantly smaller than that of the <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> group (p=0.005) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="5441">Glibenclamide</z:chebi> + <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="31654">gliclazide</z:chebi> also attenuated the progression of maximum <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>, compared with that of <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (0.041+/-0.105, 0.044+/-0.106, 0.114+/-0.131 mm/year respectively, p=0.029 and p=0.035 respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>Multivariable regression analysis implied that administration of <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="31654">gliclazide</z:chebi> significantly and independently (p&lt;0.05) reduces the progression of average <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>, compared with <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> monotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: These data indicate that <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="31654">gliclazide</z:chebi>, rather than <z:chebi fb="0" ids="5441">glibenclamide</z:chebi>, have a potent anti-atherogenic effect in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>